bluuebunny/crossref_metadata_2025_split huggingface dataset:
The plasminogen‐activation system in ovarian tumors
Authors: Pujade‐Lauraine E. , Lu H. , Mirshahi S. , Soria J. , Soria C. , Bernadou A. , Kruithof E. K. O. , Lijnen H. R. , Burtin P. 
Published: February 2007

AbstractWe studied the plasminogen activation system in tumor tissue by measuring the antigen level of the 2 plasminogen activators, tissue‐type (t‐PA) and urokinase‐type (U‐PA) and their inhibitors, plasminogen‐activator inhibitors type‐1 (PAI‐1) and type‐2 (PAI‐2) in the tissue extracts of 43 human benign and malignant ovarian tumors. U‐PA levels were significantly higher in malignant than in benign tumors. In addition, U‐PA antigen levels were higher in the metastatic tissue of advanced disease (FIGO stage III) than in the primary localized tumor (FIGO stage I/II). Also PAI‐1 concentrations tended to be higher in malignant than in benign tumors, but this difference was not statistically significant. In contrast, t‐PA levels were lower in metastatic than in non‐metastatic tumors, whereas PAI‐2 levels were unrelated to the stage of ovarian malignancy. These results were integrated in a plasminogen‐activation‐dependent malignancy index (U‐PA × PAI‐1/t‐PA). This index distinguished the different groups of benign ovarian tumors, localized and metastatic ovarian carcinomas better than U‐PA levels. It could be useful as a prognostic indicator in ovarian cancer © 1993 Wiley‐Liss, Inc.
Aberrant expression of c‐met mRNA in human gastric carcinomas
Authors: Kuniyasu Hiroki , Yasui Wataru , Yokozaki Hiroshi , Kitadai Yasuhiko , Tahara Eiichi 
Published: February 2007

AbstractWe examined mRNA expression for c‐met encoding hepatocyte growth factor receptor in 8 gastric carcinoma cell lines and 31 surgically resected gastric carcinoma tissues by Northern‐blot analysis. Two forms of the transcript, sized 7.0 kb and 6.0 kb, were found in gastric carcinomas. Transcripts of both sizes were detected at various levels in all the gastric carcinoma cell lines except the MKN‐74 line, which expressed only the 7.0‐kb form. Of the 31 gastric carcinomas, 15 (48%) over‐expressed the 7.0‐kb transcript when compared with non‐neoplastic mucosa. The 6.0‐kb transcript of the c‐met gene was expressed at considerable levels in 52% of the gastric carcinoma tissues, whereas it was only slightly expressed in non‐neoplastic mucosa of a small number of cases. An important finding was that expression of the 6.0‐kb transcript was closely correlated with tumor staging, lymph‐node metastasis and depth of tumor invasion. These results, overall, suggest that the 6.0‐kb transcript of the c‐met gene might participate in the development and progression of gastric carcinomas. © 1993 Wiley‐Liss, Inc.
Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression
Authors: Gastl Guenther A. , Abrams John S. , Nanus David M. , Oosterkamp Rianne , Silver John , Liu Frank , Chen Michael , Albino Anthony P. , Bander Neil H. 
Published: February 2007

AbstractRecent data indicate a major role for IL‐10 in suppressing immune and inflammatory reactions. To date, expression of human IL‐10 has been attributed primarily to helper T lymphocytes, activated monocytes, and neoplastic B cells, and was often found to be associated with IL‐6 expression. In this study we sought to determine whether non‐hematopoietic human tumor cell lines produce IL‐10 and, if so, what is the relationship between IL‐10 and IL‐6. Using ELISA, we determined IL‐10 and IL‐6 levels in culture supernatants of 48 cell lines established from carcinomas of the kidney, colon, breast and pancreas, malignant melanomas and neuroblastomas. IL‐6 protein was secreted by 28 of the tumor ceil lines; IL‐10 was measurable in 15 cell lines. IL‐6 secretion was maximal and most frequent in renal‐cancer cell lines, while IL‐10 production was found to be highest and most common among cell lines derived from colon carcinomas. IL‐10 in conditioned medium of one of the colon carcinoma cell lines (CCL222) was bio‐active, as demonstrated in the mouse MC/9 mast‐cell‐line assay and in human mixed‐lymphocyte reactions. In both assays, IL‐10 bio‐activity was neutralized by an anti‐IL‐10 monoclonal antibody. Expression of IL‐6 and IL‐10 was confirmed by RNA analysis using message amplification by PCR and sequencing of amplified cDNA. LPS, IL‐1 alpha, and TNF‐alpha strongly enhanced the release of IL‐6 by RCC cells, but only marginally affected IL‐10 production in colon‐carcinoma cells. IL‐10 secretion by colon‐carcinoma cells was moderately stimulated by IFN‐gamma and IL‐4. Dexamethasone suppressed the release of IL‐6, but had no inhibitory effect on IL‐10 secretion. Our results demonstrate that tumor cell lines established from certain types of human carcinomas are capable of expressing and releasing IL‐6 and/or IL‐10, suggesting a role of these cytokines in solid‐tumor development and anti‐tumor immunity. © 1993 Wiley‐Liss, Inc.
Differential over‐expression of mdr1 genes in multidrug‐resistant rat glioblastoma cell lines selected with doxorubicin or vincristine
Authors: Schott Brigitte , Bennis Sanae , Pourquier Philippe , Ries Colette , Londos‐Gagliardi Danielle , Robert Jacques 
Published: February 2007

AbstractWe have compared the pharmacological and molecular characteristics of 2 cell lines derived from the C6 rat glioblastoma, and selected for resistance either to doxorubicin (C6 0.5 line) or to vincristine (C6 IV line). Each line displays a preferential 400‐fold resistance towards the drug used for selection, the C6 IV line being especially weakly resistant to doxorubicin (13‐fold). Verapamil completely restored doxorubicin sensitivity in the C6 IV line as well as vincristine resistance in the C6 0.5 line, but could not completely reverse doxorubicin resistance in the C6 0.5 line or vincristine resistance in the C6 IV line. This suggests that specific mechanisms of resistance against each drug were added to a common P‐glycoprotein‐mediated multi‐drug‐resistance mechanism. Doxorubicin efflux was total within 2 hr in the C6 IV line, whereas it remained 8 to 10% of drug in the C6 0.5 line 4 hr after drug removal, despite a more rapid efflux of the drug in the first 30 min. This 2‐compartment behavior could be related to a special sub‐cellular distribution of doxorubicin in C6 0.5 cells. Northern and Western blot analysis of the mdr I gene and of the P‐glycoprotein expressed by the 2 resistant cell lines made it possible to quantify their degree of over‐expression; when compared with the C6 wild strain, the C6 0.5 line over‐expressed both the mdr1 gene and the P‐glycoprotein to a slightly higher level than the C6 IV line. Northern and Western blot analysis also suggested that C6 0.5 cell preferentially over‐expressed the mdr I a gene, whereas the C6 IV cells preferentially over‐expressed the mdr Ib gene. This differential over‐expression was confirmed after polymerase‐chain‐reaction amplification of the cDNA sequences transcribed from total RNA extracted from the 2 lines. It can be concluded therefore that the mdr Ia gene product is more efficient than the mdr Ib gene product in extruding anti‐cancer drugs from the cells; and that the mdr Ib gene product might preferentially extrude vincristine rather than doxorubicin. © 1993 Wiley‐Liss, Inc.
Analysis of production, purification, and cytolytic potential of bi‐specific antibodies reactive with ovarian‐carcinoma‐associated antigens and the T‐cell antigen CD3
Authors: van Ravenswaay Claasen Hedda H. , van de Griend René J. , Mezzanzanica Delia , Bolhuis Reinder L. H. , Warnaar Sven O. , Fleuren Gert Jan 
Published: February 2007

AbstractOV‐TL 3 and MOvl8 MAbs, due to their restricted specificity, have been successfully used to visualize ovarian cancer in patients and might therefore be used to develop therapies for ovarian cancer. The bi‐specific MAbs αT3/OC2 and αOC/TR (both being combinations of MOvl8 and aCD3) have been shown to lyse ovarian tumor cells in vitro. To evaluate the relative merits of MOvl8/CD3 and OV‐TL 3/CD3, the present study was undertaken in which the bi‐specific MAbs αT3/OC2 and αOC/TR, and a newly developed bi‐specific MAb, OV‐TL 3/CD3, were highly purified and compared for specificity, stability, purification and cytolytic potential. The dual specificity of the hybrid‐hybridoma supernatants was analyzed by immunohistochemistry, and by testing bi‐specific MAb‐mediated cytotoxicity against relevant target cells in the presence of effector cells. Stability testing of bi‐specific MAb‐producing hybrid‐hybridomas showed that, after sub‐cloning, clones stably produced up to 40% bi‐specific MAb even after prolonged in vitro culture. The purification of the bi‐specific fractions was performed with protein A and by ion‐exchange high‐pressure liquid chromatography, depending on the sub‐class combination of the bi‐specific MAb. The purified bi‐specific MAbs were tested for their ability to mediate target‐cell lysis with the use of cytotoxic T‐cell clones and activated peripheral‐blood lymphocytes. The purified αT3/OC2, αOC/TR, and OV‐TL 3/CD3 were all able to mediate highly specific lysis of various ovarian‐carcinoma cell lines. No correlation was found between the level of antigen expression and bi‐specific MAb‐mediated cytolysis. © 1993 Wiley‐Liss, Inc.
Invasive squamous‐cell cervical carcinoma and combined oral contraceptives: Results from a multinational study
Authors: Berry Geoffrey , Maclennan Robert , Shearman Rodney , Jelihovsky Tatiana , Booth Joan Cooper , Molina Ramiro , Martinez Luis , Salas Oriana , Dabancens Alfredo , Zhiheng Chen , Yun Tao , Wei Hu Yong , Cuadros Alvaro , Aristizabal Nubia , Modan Baruch , Ron Elaine , Alfandary Esther , Mati J. G. , Kenya Patrick , Kungu Alfred , Gatei D. , Cuevas Hector Rodriguez , Salazar Socorro Benavides , Palet Antonio , Ontiveros Patricia , Ibeziako Pat A. , Junaid T. A. , Aghediuno P. , Abioye A. A. , Apelo Ruben A. , De la Cruz Julietta R. , Baens Jose , Canlas Benjamin D. , Silpisornkosol Suporn , Pardthaisong Tieng , Charoeniam Viruch , Theetranont Choti , Boosiri Banpot , Chutivongse Supawat , Virutamasen Pramuan , Wongsrichanalai Chansuda , Sindhavananda Sermsri , Koetsawang Suporn , Rachawat Duangdao , Koetsawang Amorn , Riotton Gustave , Christopherson William M. , Melnick Joseph L. , Adam Ervin , Thomas David B. , Ray Roberta M. , Noonan Elizabeth A. , Stanford Janet L. , Rosenblatt Karin A. , Holck Susan , Meirik Olav , Farley Timothy M. M. , Thomas David B. , Ray Roberta M. 
Published: February 2007

AbstractData from a hospital‐based case‐control study collected in 11 participating centers in 9 countries were analyzed to determine whether use of combined oral contraceptives alters risk of invasive squamous‐cell cervical cancer. Information on prior use of oral contraceptives, screening for cervical cancer, and suspected risk factors for this disease were ascertained from interviews of 2361 cases and 13,644 controls. A history of smoking and anal and genital warts was obtained, and blood specimens were collected for measurement of antibodies against herpes simplex and cytomegalo viruses, from selected sub‐sets of these women, as was a sexual history from interviews of husbands. The relative risk of invasive squamous‐cell cervical carcinoma was estimated to be 1.31, with a 95% confidence interval that excluded one, in women who ever used combined oral contraceptives. Risk of this disease increased significantly with duration of use after 4 to 5 years from first exposure, and declined with the passage of time after cessation of use to that of non‐users in about 8 years. No sources of bias or confounding were identified that offered plausible explanations for these findings. The strength of these results, and their consistency with those from other studies, suggest that a causal relationship may exist between use of combined oral contraceptives and squamous‐cell cervical carcinoma. Women who have used these products for 4 or more years, and who most recently used them within the past 8 years, should receive high priority for cervical cytologic screening.
Photodynamic therapy with m‐tetrahydroxyphenylchlorin in vivo: Optimization of the therapeutic index
Authors: Ris Hans‐Beat , Altermatt Hans J. , Stewart Charles M , Schaffner Thomas , Wang Qiang , Lim Chang K. , Bonnett Raymond , Althaus Ulrich 
Published: February 2007

AbstractThe therapeutic index of meta‐tetrahydroxyphenylchlorin‐mediated photodynamic therapy (mTHPC‐PDT) was assessed in BALB/c nude mice bearing human malignant mesothelioma xenografts. Equal doses of 650 nm laser light were delivered to the tumour and to an equal‐sized area of the hind leg (control site) after i.p. administration of mTHPC. Twenty‐one groups of 6 animals each were treated under various drug‐light conditions and at drug‐light intervals ranging from 4 hr to 6 days. After light delivery the extent of tumour necrosis and the depth of alterations in normal tissue were assessed by light microscopy of standardized histological sections. A therapeutic index (T1) of mTHPC‐PDT was defined as the cross‐sectional area of tumour necrosis per depth of visible tissue injury at the control site. This T1 was strongly related to the conditions of treatment. In particular, it was increased by prolonging the drug‐light interval up to 5 days and by increasing the dose of light for any dose of drug. The most profound increase of T1 was obtained by increasing the intensity of light administered at the chosen interval while reducing the dose of drug. Our findings suggest that threshold conditions operate in PDT and have important implications for clinical application of the treatment.
Variable effects of sodium butyrate on the expression and function of the MDR 1 (P‐glycoprotein) gene in colon carcinoma cell lines
Authors: Frommel Thomas O. , Coon John S. , Tsuruo Takashi , Roninson Igor B. 
Published: February 2007

AbstractExpression of the MDRI (P‐glycoprotein) gene confers resistance to several classes of chemotherapeutic drugs (multi‐drug resistance). Colon carcinomas frequently express high levels of MDRI mRNA and P‐glycoprotein, presumably reflecting the origin of these tumors from MDRI ‐expressing normal colonic cells. In 4 colon carcinoma cell lines (SW 620, HCT‐15, DLD‐I, LS 180), MDRI expression was reported in an earlier study to be elevated after exposure to a differentiating agent, sodium butyrate (NaB). In one of these cell lines (SW 620), increased MDR I expression reportedly was not accompanied by a decrease in the accumulation or cytotoxicity of vinblastine, a P‐glycoprotein‐transported drug, suggesting a possible functional abnormality of NaB‐induced P‐glycoprotein. We have re‐examined the effect of NaB on MDRI /P‐glycoprotein expression and function in the same colon carcinoma cell lines. NaB treatment induced differentiation‐related changes and increased expression of MDRI mRNA in all 4 cell lines. A major increase in MDRI mRNA and P‐glycoprotein expression was observed in only one line, SW 620. This increase, however, was accompanied by a commensurate increase in the activity of P‐glycoprotein, indicating that the induced protein was fully functional. NaB treatment caused a relatively minor increase in MDRI mRNA expressed in the other 3 cell lines. Two of these lines showed a detectable increase in the P‐glycoprotein expression and function, but in the third line (LS 180) P‐glycoprotein was undetectable either before or after exposure to NaB. The magnitude of MDRI induction by NaB showed no apparent correlation with differentiation‐related changes induced by this agent.
A polymerase‐chain‐reaction assay for the specific identification of transcripts encoded by individual carcinoembryonic antigen (CEA)‐gene‐family members
Authors: Thompson J. , Mössinger S. , Reichardt V. , Engels U. , Beauchemin N. , Kommoss F. , von Kleist S. , Zimmermann W. 
Published: February 2007

AbstractCarcinoembryonic antigen (CEA) is a tumor marker that belongs to a family of closely related molecules with variable expression patterns. We have developed sets of oligonucleotide primers for the specific amplification of transcripts from individual CEA‐family members using the reverse transcriptase/ polymerase chain reaction (RT/PCR). Specific primer sets were designed for CEA, non‐specific cross‐reacting antigen (NCA), biliary glycoprotein (BGP), carcinoembryonic antigen gene‐family members 1, 6 and 7 (CGMI, CGM6 and CGM7), and one set for all pregnancy‐specific glycoprotein (PSG) transcripts. Primers were first tested for their specificity against individual cDNA clones and product‐hybridization with internal, transcript‐specific oligonucleotides. Total RNA from 12 brain and 63 gynecological tumors were then tested for expression of CEA‐related transcripts. None were found in tumors located in the brain, including various mesenchymal and neuro‐epithelial tumors. CEA and NCA transcripts were, however, present in an adenocarcinoma located in the nasal sinuses. In ovarian mucinous adenocarcinomas, we always found co‐expression of CEA and NCA transcripts, and occasionally BGP mRNA. CEA‐related transcripts were also found in some serous, endometrioid and clear‐cell ovarian carcinomas. CEA, NCA and BGP transcripts were present in endometrial carcinomas of the uterus and cervical carcinomas, whereas uterine leiomyomas were completely negative. No transcripts were found from CGM 1, CGM6, CGM7 or from PSG genes in any of the tumors tested. The PCR data were compared with immunohistochemical investigations of ovarian tumors at the protein level using CEA (26/3/13)‐, NCA‐50/90 (9A6FR) and NCA‐95 (80H3)‐specific monoclonal antibodies.
Immunogenic properties of retroviral protein p15e from drug‐treated murine mastocytoma P815
Authors: Grohmann U. , Fioretti M. C. , Binaglia L. , Belladonna M. L. , Bianchi R. , Puccetti P. 
Published: February 2007

AbstractA triazene‐xenogenized tumor sub‐line was derived from the mouse mastocytoma cell line P815 following several transplant generations in vivo on DTIC. The highly immunogenic P815/ DTIC variant line expressed new CTL‐defined antigens. Novel antigens were also detected by antibodies in immunoprecipitation and by Western blot analysis. Upon immunoprecipitation of metabolically labeled cells, one such variant‐specific 20‐kDa antigen was shown to be related to retroviral envelope protein p15E. When injected intrasplenically into recipient mice, the electroblotted nitrocellulose‐bound 20‐kDa antigen resulted in increased frequency in CTL precursors to P815/DTIC cells. In addition to previous data in the L5I78Y/DTIC tumor‐model system, these data suggest that expression of aberrant, retrovi‐rus‐related proteins may be a common finding in different parental tumors xenogenized by triazene treatment.
The association between epstein‐barr virus and chinese hodgkin's disease
Authors: Zhou Xiao‐Ge , Hamilton‐Dutoit Stephen J. , Pallesen Gorm , Yan Qin‐Han 
Published: February 2007

AbstractEpstein‐Barr virus (EBV) can be detected in Hodgkin and Reed‐Sternberg (HRS) cells in about one‐half of cases of Hodgkin's disease (HD) in Western countries. To determine whether EBV is also associated with HD in a developing country such as China, we studied paraffin sections from 28 Chinese cases of HD for expression of latent membrane protein‐1 (LMP‐1) and EBV‐encoded small RNA (EBER‐I), using immuno‐histology and RNA/RNA in situ hybridization respectively. The cases were selected from a large series of Chinese lymphomas following histological and immunophenotypical revision. EBV gene expression was found in HRS cells in 17/28 cases, and was related to histological sub‐type, being present in 10/11 of mixed cellularity, 6/14 nodular sclerosis, 0/1 lymphocytic predominance, 0/1 lymphocytic depletion, and 1/1 unclassified HD. The 2 methods for detecting EBV gene expression gave similar results, except in one case of nodular sclerosis, in which HRS cells were negative for EBER‐1, but weakly positive for LMP‐1. In 5/12 cases with EBER‐negative HRS cells, rare small or medium‐sized lymphocytes expressed EBER‐1 but not LMP‐1. These results suggest that (i) Chinese HD is frequently associated with EBV; (ii) the proportional frequency and sub‐type distribution of EBV‐positive HD are similar in China and in the West; (iii) both LMP‐1 immunohistology and EBER in situ hybridization reliably detect EBV in HRS cells in routine biopsies, but the former is simpler and less resource‐consuming to perform.
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
Authors: Toi Masakazu , Tominaga Takeshi , Kashitani Jitsuo 
Published: February 2007

AbstractClinical importance of tumor angiogenesis, especially its significance as a prognostic indicator, was examined in 125 primary breast‐cancer patients. The grade of neovascularization was assessed by the vessel density which was obtained by immunocytochemical staining for factor VIII antigen. Postoperative survey demonstrated that the vessel density is a statistically significant predictor of relapse‐free survival (median follow‐up period: 62 months). Patients with over 100 counts of factor‐VIII antigen‐positive cells per 200 x field in the most active areas of neovascularization showed significantly poorer prognosis than those with less than 100 counts. The prognostic value of the vessel density was also confirmed by another evaluation method using immunocytochemical staining to CD‐31 which is a platelet/endothelial cell adhesion molecule. A significant difference in relapse‐free survival rate was shown between patients having higher counts of CD‐31 positive cells and those having lower counts. Breakdown analysis stratified by nodal status showed that the vessel density was a significant prognostic indicator in node‐negative and node‐positive patients. Multivariate analysis indicated that the vessel density is an independent prognostic indicator in primary breast‐cancer patients.
Human papillomavirus in vulvar squamous‐cell carcinoma and in normal vulvar tissues: A search for a possible impact of HPV on vulvar cancer prognosis
Authors: Hørding Ulla , Bock Johannes E. , Kringsholm Birgitte , Andreasson Benny , Visfeldt Jakob , Daugaard Søren 
Published: February 2007

AbstractParaffin‐embedded sections of vulvar squamous‐cell carcinomas and of normal vulvar tissues were examined for HPV types 6, 11, 16, 18 and 33 by the polymerase chain reaction. Overall, 19 of 62 tumours harboured HPV DNA of types 16, 18 or 33. HPV types 6 and 11 were not detected. HPV DNA was found in 61% of tumours with adjacent intraepithelial neoplasia (VIN III), and in 13% of tumours without associated VIN III. HPV DNA was not detected in any of 101 normal vulvar tissues. HPV DNA was found more often in younger women, in patients with VIN III‐associated tumours, and in those with multicentric anogenital neoplasia. This points to the existence of a subset of vulvar carcinomas preceded by intraepithelial neoplasia, with HPV as a major factor in carcinogenesis. HPV also seems to be an important factor in the development of multiprimaries in these patients. The 2 groups of patients with vulvar carcinoma did not differ with regard to prognosis, as estimated by the risk of recurrence after primary surgery.